Aquestive Therapeutics Inc (AQST) Stock Price, Quote & News

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 941 1900

Website: www.aquestive.com

Address:

30 Technology Drive, Warren, United States

ponyboy37 Aug. 19 at 2:15 AM

$AQST been watching this stock everyday since the CRL drop….i can see the inflection point occurred before earnings. Pre party has officially started.

0 · Reply

OustDB_formerly_nomas Aug. 19 at 12:05 AM

$AQST will we ever get an AMLX like jump?? i know it is garbage, but sometimes garbage makes $$. give me some garbage!!

0 · Reply

LDstocks2023 Aug. 18 at 8:25 PM

$AQST atta boy danny barber! 25k shares sold one month…then 25k the next month…then 25k the following month...thats super bullish!

1 · Reply

Dcastle Aug. 18 at 8:17 PM

$AQST Look at the volume 😍😍😍.....people know about that horizon.

2 · Reply

BigGainTom Aug. 18 at 8:04 PM

$AQST >5 M shares traded today. >3M shares traded yesterday. But stock price has been pretty flat. That means heavy accumulation.

1 · Reply

BigGainTom Aug. 18 at 8:00 PM

$AQST $IOVA $FLNT Each closed over crucial resistances today!

0 · Reply

LDstocks2023 Aug. 18 at 8:00 PM

$AQST solid finish…not

0 · Reply

prototyper Aug. 18 at 7:07 PM

$AQST We should just jump straight to 5+ tomorrow. 4s are boring now

0 · Reply

Master_P_ Aug. 18 at 3:38 PM

$AQST Took me way too long to do it, but do yourselves a favor and mute that LD guy... Unless you like to trade on emotions, then he's your guy.

1 · Reply

USAEquityResearch Aug. 18 at 2:50 PM

$AQST 📊 USAEquityResearch ▲ 4.29 (+0.94%) Trend: Bullish 📈 RSI (14): 70.9 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 4.41 Support: 3.60 20-MA: 3.96 | 50-MA: 4.14 Educational content only. Not financial advice.

0 · Reply

Aquestive Therapeutics Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Aquestive Therapeutics Earnings release: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Aquestive Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Aquestive Therapeutics Slides: Q2 2026

2026-08-11T20:10:50.000Z - 7 days ago

Aquestive Therapeutics reports Q2 EPS (18c), consensus (12c)

2026-08-11T20:10:29.000Z - 7 days ago

Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $50.51M

Aug 11, 2026, 4:01 PM EDT - 7 days ago

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Jul 29, 2026, 7:00 AM EDT - 21 days ago

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

2026-06-26T20:25:27.000Z - 7 weeks ago

Aquestive Therapeutics files to sell 230,271 shares of common stock for holders

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

Aquestive Therapeutics Registration statement: Registration filing

Jun 10, 2026, 9:30 AM EDT - 2 months ago

Aquestive Therapeutics Transcript: AGM 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Aquestive Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Aquestive Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Aquestive Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Aquestive Therapeutics Slides: Q1 2026

2026-05-13T20:36:49.000Z - 3 months ago

Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)

May 13, 2026, 4:01 PM EDT - 3 months ago

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 9:31 AM EDT - 3 months ago

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 6, 2026, 7:00 AM EDT - 3 months ago

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Aquestive Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Aquestive Therapeutics Proxy statement: Proxy filing

2026-04-24T11:41:01.000Z - 4 months ago

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

Apr 16, 2026, 9:00 AM EDT - 4 months ago

AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

2026-04-15T13:51:38.000Z - 4 months ago

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

Apr 9, 2026, 8:23 AM EDT - 4 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

2026-03-30T11:16:34.000Z - 5 months ago

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

2026-03-20T11:11:07.000Z - 5 months ago

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

Mar 20, 2026, 7:00 AM EDT - 5 months ago

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

Mar 12, 2026, 9:00 AM EDT - 5 months ago

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Mar 10, 2026, 8:25 AM EDT - 5 months ago

Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 4:01 PM EDT - 5 months ago

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 10:40 AM EDT - 5 months ago

Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 2:01 PM EST - 5 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-03-05T18:20:15.000Z - 5 months ago

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Slides: Q4 2025

2026-03-04T21:20:27.000Z - 5 months ago

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

2026-03-04T21:19:36.000Z - 5 months ago

Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M

Mar 4, 2026, 4:01 PM EST - 5 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 12:00 PM EST - 6 months ago

Aquestive Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 6 months ago

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 7:00 AM EST - 6 months ago

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

2026-02-20T12:06:15.000Z - 6 months ago

Aquestive announces poster presentations on Anaphylm at AAAAI meeting

2026-02-18T12:11:06.000Z - 6 months ago

Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer

2026-02-03T13:46:32.000Z - 7 months ago

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

2026-02-02T19:05:09.000Z - 7 months ago

Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating

2026-02-02T15:45:14.000Z - 7 months ago

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

Feb 2, 2026, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Transcript: Status update

Feb 2, 2026, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Press release: Status update

Feb 2, 2026, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Slides: Status update

Feb 2, 2026, 7:10 AM EST - 7 months ago

US FDA declines to approve Aquestive's oral drug for allergic reactions

Feb 2, 2026, 7:00 AM EST - 7 months ago

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Jan 9, 2026, 7:00 AM EST - 7 months ago

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Dec 4, 2025, 10:00 AM EST - 9 months ago

Aquestive Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 8:00 AM EST - 10 months ago

Aquestive Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Aquestive Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Aquestive Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Aquestive Therapeutics Slides: Q3 2025

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

ponyboy37 Aug. 19 at 2:15 AM

$AQST been watching this stock everyday since the CRL drop….i can see the inflection point occurred before earnings. Pre party has officially started.

0 · Reply

OustDB_formerly_nomas Aug. 19 at 12:05 AM

$AQST will we ever get an AMLX like jump?? i know it is garbage, but sometimes garbage makes $$. give me some garbage!!

0 · Reply

LDstocks2023 Aug. 18 at 8:25 PM

$AQST atta boy danny barber! 25k shares sold one month…then 25k the next month…then 25k the following month...thats super bullish!

1 · Reply

Dcastle Aug. 18 at 8:17 PM

$AQST Look at the volume 😍😍😍.....people know about that horizon.

2 · Reply

BigGainTom Aug. 18 at 8:04 PM

$AQST >5 M shares traded today. >3M shares traded yesterday. But stock price has been pretty flat. That means heavy accumulation.

1 · Reply

BigGainTom Aug. 18 at 8:00 PM

$AQST $IOVA $FLNT Each closed over crucial resistances today!

0 · Reply

LDstocks2023 Aug. 18 at 8:00 PM

$AQST solid finish…not

0 · Reply

prototyper Aug. 18 at 7:07 PM

$AQST We should just jump straight to 5+ tomorrow. 4s are boring now

0 · Reply

Master_P_ Aug. 18 at 3:38 PM

$AQST Took me way too long to do it, but do yourselves a favor and mute that LD guy... Unless you like to trade on emotions, then he's your guy.

1 · Reply

USAEquityResearch Aug. 18 at 2:50 PM

0 · Reply

LDstocks2023 Aug. 18 at 2:28 PM

$AQST aquestive continues down. spry continues up.

0 · Reply

TheMagicalTomato Aug. 18 at 2:19 PM

$AQST Don’t forget AQST owns all of their manufacturing facilities…

1 · Reply

Merlintrader Aug. 18 at 9:26 AM

Aquestive Therapeutics ($AQST) Stock Hub 2026 https://www.merlintrader.com/aquestive-therapeutics-stock-hub/

0 · Reply

Shadowlake21 Aug. 18 at 3:09 AM

$AQST SPRY: Mid-2022 to mid-2023: Stock around $7. Sept 2023: FDA issued a Complete Response Letter (CRL) → stock crashed to ~$2.50-$3. Aug 2024: FDA approved neffy 2 mg (1 mg followed in 2025) → stock rallied to $17-18+ AQST: Climbed higher $7.55 into the Anaphylm NDA, got a CRL (Jan 30, 2026) purely on packaging/human-factors (pouch opening, placement, etc.-no CMC, no efficacy, no safety questions on the core data) → sold off → now sitting ~$4.40. From $4.40, a clean run to $18 on approval + launch hype is the classic biotech "fix the last regulatory risk and go vertical" move. This is the sequel. Enjoy the ride. Bullish

1 · Reply

kibli Aug. 18 at 12:08 AM

$AQST This was $7.5 last year before sell-off anticipation and regulatory jitters this past Jan when it dropped to about $6.5. Now substantially derisked in its regulatory path for Anaphylm we should see an even better climb.

2 · Reply

wowwwwww2 Aug. 17 at 9:55 PM

$AQST when 8

0 · Reply

ClearCities Aug. 17 at 9:23 PM

$AQST dan barber when is he coming on tv and showing everyone his film on his iphone

2 · Reply

ShibWillow Aug. 17 at 8:57 PM

Looks like Volume is shifting to MLEC now 🚀 MLEC has 573k shares remaining to public Look at what WETO / IPST did on similar share numbers today. MLEC getting squeezed now - Added a big position for a parabolic run! $BIDU $AQST $SLS $DRMA new

2 · Reply

Teppermp Aug. 17 at 8:32 PM

$AQST What a great job on the packaging.

1 · Reply

ae1213 Aug. 17 at 7:22 PM

$AQST $SPRY it is funny (and very shortsighted) how this board shows market cap obsession aqst vs. spry. I don’t think you have any idea what is ahead for this aqst and it’s deceiving management

2 · Reply

BigGainTom Aug. 17 at 7:09 PM

$AQST Thank you for your feedback about the FDA. Meanwhile, don't you have a dog to mutilate?

1 · Reply

ae1213 Aug. 17 at 7:03 PM

$AQST it increasingly looks like fda will never approve this as a rescue med for children due to the poor pk data (never mind compsny spin). 100 mg/ml is not a biomarker fda ever mentioned. With the black box warning this is as good as CRL which will come really soon

0 · Reply

Market Cap	538.45M
Revenue (ttm)	44.55M
Net Income (ttm)	-83.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-188.06%
Debt to Equity Ratio	-0.90

Volume	5,449,600
Avg Vol	2,586,532
Day's Range	N/A - N/A
Shares Out	125.51M
Stochastic %K	60%
Beta	1.49
Analysts	Strong Sell
Price Target	$8.89